Toxicity Monitoring for Bleomycin, Etoposide, and Cisplatin (BEP) Chemotherapy

Bleomycin-Specific Toxicities

The American Society of Clinical Oncology recommends that bleomycin-induced pneumonitis (BIP) be closely monitored, as it occurs in approximately 10% of germ cell tumor patients and is life-threatening in 20% of these cases 1
The combination of bleomycin with cisplatin significantly increases pulmonary toxicity risk because cisplatin-induced renal damage reduces bleomycin clearance, leading to drug accumulation 1
High-risk features for BIP include age >40 years, which substantially increases the risk compared to younger patients 1
Concomitant oxygen therapy and prior or concurrent mediastinal radiotherapy are also high-risk features for BIP 2

The National Comprehensive Cancer Network recommends monitoring for acute reversible decrease in glomerular filtration rate, which occurs in most patients, and some sustain irreversible damage with up to 30% reduction in GFR 3
Peripheral neuropathy occurs after prolonged therapy, but can occur after a single dose, and symptoms may begin 3-8 weeks after the last dose and may be irreversible 3
Hypomagnesemia may persist for more than 6 years in some patients 3

The National Comprehensive Cancer Network recommends monitoring for secondary malignancies, such as acute leukemia, which is reported rarely, typically with other leukemogenic agents 4

The European Society for Medical Oncology recommends avoiding dose reductions unless absolutely necessary to maintain cure rates, and postponing treatment for a maximum of 3 days only for fever, neutrophils <500/ml, or platelets <100,000/ml 5, 6
The American Society of Clinical Oncology recommends considering prophylactic G-CSF only after serious infectious complications in prior cycle 6

The American Society of Clinical Oncology recommends offering semen cryopreservation before orchiectomy for all appropriate patients, as alkylating agent-based chemotherapy is associated with higher infertility risk in both sexes 2, 5

The National Comprehensive Cancer Network recommends monitoring lipids, blood pressure, and cardiovascular risk factors long-term, as testicular cancer survivors have increased cardiovascular mortality risk 3
The American Thoracic Society recommends restricting smoking and monitoring for respiratory disease, as respiratory disease mortality is increased in chemotherapy-treated patients 2